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Abstract 
 
Metastatic disease to the adrenal glands can occur in a wide array of 
malignancies. With the increased use of abdominal imaging, these lesions 
are diagnosed with more frequency. Diagnostic and laboratory evaluation 
is essential for the differentiation of benign lesions from primary 
malignant adrenal tumors or extra-adrenal metastasis. Computed 
tomography (CT) and magnetic resonance imaging (MRI) characteristics, 
as well as the adjunctive use of immunocytochemical techniques on 
biopsy specimens, can allow accurate identification of metastatic lesions. 
Surgical management of metastastic lesions is appropriate in selected 
patients, primarily when representing the solitary site of metastatic 
disease. The surgical approach, while debatable, can de done either 
through open surgery or laparoscopically. Either approach appears 
comparable in terms of oncologic efficacy in the carefully selected patient, 
although laparoscopic adrenalectomy is associated with decreased pain 
and improved convalescence. The surgeon’s skill in laparoscopic 
technique, appropriate patient selection, and the ability to adhere to 
oncologic principles, including complete excision without tumor spillage, 
are of utmost importance when deciding the appropriate surgical 
intervention. 
 
 
 
The adrenal gland is a common site of metastasis and can be 
afflicted by malignancies from a multitude of primary sites.1-3 The rich 
sinusoidal blood flow and multiple pathways of arterial blood supply may 
contribute to the high incidence of metastatic  implantation.1,3 In one 
autopsy review of 1,000 patients with malignancy, metastases to the 
adrenal glands were found in 27% of patients.2 The most common sites 
metastasizing to the adrenal glands are breast, lung, gastrointestinal 
tract, skin (melanomas), and kidney. Lung and breast cancers have been 
found to account for approximately 39% and 35% of adrenal metastases, 
respectively, and adrenal metastases can be seen in up to 40% to 50% of 
patients with melanomas and liver or renal cell cancers.2-4 
 
Patients with adrenal metastasis are typically asymptomatic but can 
uncommonly present with back pain, retroperitoneal hemorrhage, or 
adrenal insufficiency.1,5  In one study, symptomatic metastases were 
larger in size when compared to asymptomatic lesions and also were 
associated with a significantly younger patient population.5 
Overwhelmingly, however, the majority of adrenal metastases are either 
discovered incidentally during the staging workup for a primary 
malignancy or identified on repeat radiological studies for surveillance 
after initial treatment. Over a 30-year period, Lam and Lo found that 
adrenal metastases were most frequently discovered within a relatively 
brief period of time after detection of the primary malignancy (median 
latent period, 7 months), with less than 2% of cases having metastases 
to the adrenals more than 5 years after diagnosis.5 
 
Imaging 
 
Improvements in imaging techniques have allowed the ready 
detection and characterization of adrenal gland metastases.6-12 Computed 
tomography (CT) with and without oral and intravenous iodinated contrast 
is useful in assessing adrenal lesions. Oral contrast should be given to 
distinguish the adrenal glands from surrounding organs. On CT, 
metastatic lesions are generally nonspecific and can have a wide array of 
radiographic features. The size can vary from less than a centimeter to a 
large mass. They may have a discrete focus or be multifocal; they can be 
smooth, irregular, or have a lobulated contour. Lesions can be unilateral 
or bilateral, can show evidence of local invasion, and may be associated 
with hemorrhage. Calcifications are a rare finding in metastatic lesions, 
but necrosis may be present. Intracellular lipid content and vascular 
enhancement are two CT criteria that can be useful in differentiating 
benign adenomas from malignant adrenal masses.6 Metastatic lesions 
typically have low levels of intracytoplasmic fat in the adrenal cortex as 
compared to adenomas (70% of cases) and will have lower attenuation 
than adenomas on noncontrast CT.6,7,10,11 After the administration of 
iodinated contrast there is usually a more obvious heterogeneous 
enhancement pattern compared to adenomas and a significantly delayed 
contrast material washout.6,7,9 
 
Magnetic resonance imaging (MRI) is another useful tool for 
evaluating metastatic lesions to the adrenal glands. MRI can be used in 
patients who have a contraindication to intravenous contrast, particularly 
those with an iodine allergy or those in renal insufficiency. T1-weighted 
magnetic resonance images of metastatic tumors have a signal intensity 
that is similar to adrenal adenomas and may be confused with benign 
lesions.6,7 On T2-weighted imaging, lesions are likely to be heterogeneous 
and hyper-intense when compared to liver.  T2-weighted imaging with 
opposed-phase imaging (in and out of phase) will show no decrease in 
intensity secondary to the decreased lipid content in the mass. After the 
administration of intravenous gadoliniumcomplex, most tumors are 
hyper-intense and show heterogeneous enhancement. Using T2-weighted 
fat-suppressed images, MRI may distinguish between normal and 
neoplastic tissue.7  
 
Ultrasonography may detect adrenal lesions that are larger than 2 
cm. However, ultrasound has not been as useful as CT in the evaluation 
of metastatic adrenal lesions.13,14 The sensitivity and specificity for 
ultrasound were found to be 79% and 61%, respectively, as compared to 
84% and 98% for CT.13 Operator experience, body habitus, bowel gas, 
and lack of specific imaging patterns are all impeding factors. Preliminary 
results with positron emission tomography (PET) have shown some 
promise in differentiating malignant lesions using 18-fluorodeoxyglucose, 
but further studies are needed to better define the role of this technology 
in assessing adrenal lesions.6 
 
Clinical and Serological Diagnosis 
 
Establishing a diagnosis of metastatic disease versus benign disease 
is paramount. As discussed, metastatic lesions can have nonspecific 
findings on imaging and thus can overlap with benign adrenal masses in 
size and radiological detail. Patients should be questioned for signs and 
symptoms of a metabolically active primary adrenal tumor, such as 
hypertension, tachycardia, headache, palpitations, hirsutism, or change in 
body habitus. A physical examination should be performed looking for the 
stigmata of the other etiologies of adrenal pathology, including 
examination for lymphadenopathy, thyroid lesions, and genitourinary 
abnormalities.  Serum electrolytes, as well as urine and serum analysis 
for aldosterone, cortisol, sex hormone steroids, and catecholamines and 
their metabolites such as metanephric acid, should be performed to 
evaluate for primary adrenal tumors.15,16 
 
Biopsy 
 
Fine-needle aspiration (FNA) with CT guidance can be performed 
safely and is highly sensitive and specific for diagnosing adrenal 
metastasis.17,18 FNA also is useful for defining a primary malignancy of 
unknown origin. The accuracy of FNA has improved with advances in 
immunocytochemistry techniques, which have a specificity and sensitivity 
reported to be as high as 85% to 94% and 100%, respectively.17 The best 
diagnostic results are obtained when a cytopathologist and 
cytotechnology assistant are present while specimens are obtained at the 
time of FNA. Some cytologic indicators of metastatic lesions are increased 
nuclear hyperchomasia, prominent nucleoli, necrotic debris, and intact 
cells with increased nuclear/cytoplasmic ratios. The complication rate of 
FNA have been reported to be approximately 3.0%, which may include 
hemorrhage, infection, theoretical risk of tumor tract seeding, and 
capsular disruption.17,19 There is also the risk of biopsy of an unrecognized 
pheochromocytoma, which can cause life-threatening hemodynamic 
instability. In a review by Fassancht et al, in patients with a 
nonmetabolically active adrenal mass and inconclusive imaging, the 
authors recommended an adrenal biopsy in the absence of other 
metastasis.16 
 Surgical Management of Adrenal Metastasis 
 
Surgical management of an adrenal lesion is indicated for the 
removal of functional and nonfunctional tumors, including 
pheochromocytoma, solid adrenal masses not meeting radiographic 
criteria as benign lesions, and lesions greater than 5 cm.20 Open surgical 
adrenalectomy can be performed by a variety of means, including 
posterior and modified posterior, flank, and transabdominal approaches. 
Laparoscopic adrenalectomy has emerged as the treatment of choice for 
benign functioning and nonfunctioning adrenal disorders requiring 
surgery. Most commonly, a transperitoneal approach is performed, but 
retroperitoneal laparoscopy can be used.20 The choice of technique and 
approach depends largely on the surgeon’s experience and preference, 
size and location of the tumor, body habitus, previous intra-abdominal 
surgery, or previous adhesions. Contraindictions to laparoscopy include 
pregnancy, large tumors (_8 cm), or if primary invasive adrenocortical 
carcinoma is suspected on imaging. 20,21 Other relative contraindications 
include morbid obesity, prior intraabdominal surgery, and large 
pheochromocytomas. 
 
Several series confirm that surgical management of a metastatic 
adrenal lesion does improve survival in select patients and can lead to 
potential cure.19,22-32 In a series reported by Higashiyama et al, lung 
cancer patients with isolated metastatic disease to the adrenal gland who 
underwent surgical resection followed by adjuvant chemotherapy or 
radiotherapy fared much better than patients treated non-operatively.27 
This study demonstrated a median survival of less than 6 months for 
patients treated medically, and survival benefit of greater than 9 months 
in the surgical group, with one patient showing no disease progression 
after 40 months. Luketich and Burt found a 3-year actuarial survival of 
38% in solitary adrenal metastatic lesions from non-small cell lung cancer 
managed with chemotherapy followed by adrenalectomy compared with 
chemotherapy alone.26 The survival in the surgery group was significantly 
improved with a median of 31 months, versus 8.5 months, and all of the 
patients in the chemotherapy group without surgery died within 22 
months.26 
 
Several studies have tried to identify patients who may benefit from 
surgical excision of metastatic adrenal lesions. Adrenalectomy has been 
found to be most beneficial when the primary cancer is controllable and 
when there is no evidence of extra-adrenal metastases. 30 Siemer et al 
examined renal cell cancer patients and noted that patients with a solitary 
adrenal metastasis achieved a significant tumor-specific survival benefit 
with a median survival of 68 months compared to a median survival of 10 
months in those patients with additional metastatic foci.25 Risk factors 
such as the site of the primary cancer, size, histology, primary tumor type 
(adenocarcinoma possibly being more favorable), presence of other 
distant metastases, local invasion, and a lengthy disease-free interval 
after initial diagnosis appear to impact on cancer survival, but these risk 
factors have been somewhat variable.4,25-33 
 
The optimal surgical approach for adrenalectomy for metastatic 
lesions, either laparoscopic or open surgery, is somewhat controversial. 
The majority of data regarding improved survival after adrenalectomy 
have focused primarily on open surgical techniques. In a series from 
Memorial Sloan-Kettering Cancer Center, Kim et al examined 37 patients 
who underwent open adrenalectomy, and found a 5-year survival of 24% 
(median survival, 21 months).29 They found that complete resection and a 
disease-free interval of greater than 6 months were predictors of survival. 
Advocates of open adrenalectomy voice many concerns with laparoscopy, 
such as the possibility of tumor seeding and subsequent carcinomatosis 
due to carbon dioxide insufflation, violation of the adrenal gland and 
tumor spillage, the possible immunosuppressive affects of the 
pneumoperitoneum, and potential port site metastasis as reasons to avoid 
laparoscopic surgery.28,30,34,35 Additionally, Kebebew et al demonstrated 
that inadvertent laparoscopic resection of clinically unsuspected 
adrenocortical carcinoma exhibited a high local recurrence rate.19 Gerber 
et al reported on their experience with laparoscopic adrenalectomy for 
lung cancer patients with a solitary metastasis to the adrenal gland.36 
They found that these patients had an inflammatory reaction that made 
dissection during laparascopy more difficult than with benign disease to 
the adrenal gland, and concluded that lesions greater than 5 cm are less 
amenable to laparoscopic adrenalectomy and have a higher rate of open 
conversion. 
 
The incidence of port site metastasis has been estimated to be from 
0% to 6.25%.35 Causes of port site metastasis can be grouped into 
several categories: tumor aggressiveness (type of tumor and its natural 
behavior), local wound factors (implanting in the early stages of wound 
healing, tumor cell adherence to wound margins, and release of growth 
factors), host immune response, and laparoscopy-related factors (ie, type 
of gas used for insufflation, surgical manipulation, tumor spillage).35 In 
their review of the urologic literature, Tsvian et al found nine cases of port 
site metastasis.  The putative causative factors of port site metastasis 
were high stage or grade primary tumor, violation of tumor boundaries, 
intracorporeal morcellation of the tumor specimen, and disuse of an 
entrapment bag during specimen retrieval. Other potential risk factors 
were pre-existing immunosuppression and the presence of ascites.35,37  
 
There have been contradictory reports on the role of the 
pneumoperitoneum as the cause of port site metastasis and 
carcinomatosis.38-40 In an novel study by Ikramuddin et al, carbon dioxide 
effluent recovered from patients with cancer during laparoscopy was 
examined. 40 The authors concluded that malignant cells are aerosolized 
in laparoscopic surgery, but in patients without carcinomatosis, 
aerosolization is unlikely to contribute to port site metastasis. 
 
Many proponents of laparoscopic surgery suggest that laparoscopic 
adrenalectomy is oncologically comparable to open surgery for the 
management of metastatic lesions to the adrenal in the selected patient. 
In regards to port site seeding, proponents state that open adrenalectomy 
is not exempt from wound recurrences. There is an approximately 0.4% 
chance of metastasis in surgical scars after open surgery for renal cell 
carcinoma.41 Laparoscopic adrenalectomy may have several advantages 
over open surgical approaches.  When compared to open surgery, 
laparoscopy has demonstrated superior operative times, analgesic 
requirements, postoperative complications, hospital stay, and mean 
operative blood loss.42,43 Laparoscopic adrenalectomy appears to confer 
the same survival benefit as open surgery.31,44 Sarela et al found no 
difference in the median survival between open adrenalectomy and 
laparoscopic adrenalectomy.45 In another series, 31 patients underwent 
laparoscopic adrenalectomy for metastatic lesions from several primary 
tumors, primarily colon, lung, and renal cell cancers.30 The 5-year 
actuarial survival rate was 40% with a median follow-up of 26 months, 
which was favorable when compared to historical open adrenalectomy 
series. The authors emphasized that proper patient selection was critical, 
and small organ-confined adrenal masses were best suited for a 
laparoscopic procedure. Specific contraindications to laparoscopic 
adrenalectomy were irregular adrenal masses with peri-adrenal infiltration 
into adjacent organs. The authors suggested that a laparoscopic approach 
should be abandoned if there are concerns regarding the adequacy of 
wide excision, and care should be taken not to violate the adrenal mass, 
to avoid tumor spillage, and to remove the specimen intact rather than 
through morcellation, with the use of a laparoscopic bag to withdraw the 
specimen.  
 
Alternative approaches to the treatment of metastatic disease to the 
adrenal gland have been examined. 43,44,46,47 Percutaneous radiofrequency 
ablation (RFA) has exhibited some promise in treating malignant adrenal 
tumors.43,44 RFA utilizes alternating radiofrequencies, which generate heat 
and lead to tissue necrosis and destruction. In a preliminary study of RFA 
of metastatic adrenal lesions, tumor recurrence occurred in two of 11 
patients after RFA treatment.43  Percutaneous ethanol ablation is another 
non-invasive approach that has been investigated for adrenal tumors. 
Ethanol is cytotoxic and thrombogenic and has shown promise in short-
term studies.46,47 Although the specific roles for RFA and ethanol ablation 
have not been established and long-term data are still pending, these 
percutaneous techniques may have promise for patients who are non-
operative candidates or those who refuse surgical intervention. 
 
Conclusion 
 
The surgical management of adrenal metastatic lesions has shown 
benefit in the survival of select patients with a variety of primary tumors. 
Adrenal metastesectomy also has exhibited success when used as an 
adjunct to chemotherapy, and has been found to be more successful than 
chemotherapy and radiation alone. Controversy remains over the use of 
laparoscopic adrenalectomy, although in a number of studies there seems 
to be at least a parallel survival benefit when compared to open 
adrenalectomy, with improved convalescence. The importance of patient 
selection, surgeon comfort level and experience, adequate surgical 
planning, and adherence to oncologic principles cannot be overstated 
when performing laparoscopic adrenalectomy for metastastic lesions. 
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